DAPK promoter methylation status correlates with tumor metastasis and poor prognosis in patients with non-small cell lung cancer

Cancer Biomarkers

Volumn 15, Issue 5, 2015, Pages 609-617

  Zhang, Jun ^a   Yu, Xiao Ling ^a   Zheng, Guo Feng ^a   Zhao, Fei ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

clinicopathological features; Death associated protein kinase (DAPK); metaanalysis; non small cell lung cancer; prognosis

Indexed keywords

DEATH ASSOCIATED PROTEIN KINASE; TUMOR MARKER;

ARTICLE; CANCER GENETICS; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; DNA METHYLATION; GENETIC ASSOCIATION; HISTOLOGY; HUMAN; LUNG METASTASIS; NON SMALL CELL LUNG CANCER; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; SYSTEMATIC REVIEW; GENETICS; META ANALYSIS; METASTASIS; PATHOLOGY; PROGNOSIS; SURVIVAL ANALYSIS;

BIOMARKERS, TUMOR; CARCINOMA, NON-SMALL-CELL LUNG; DEATH-ASSOCIATED PROTEIN KINASES; DNA METHYLATION; HUMANS; NEOPLASM METASTASIS; PROGNOSIS; PROMOTER REGIONS, GENETIC; SURVIVAL ANALYSIS;

EID: 84941279383     PISSN: 15740153     EISSN: 18758592     Source Type: Journal    
DOI: 10.3233/CBM-150501     Document Type: Article

References (51)

1. Liu XH, Liu ZL, Sun M, Liu J, Wang ZX, De W, The long non-coding RNA HOTAIR indicates a poor prognosis and promotes metastasis in non-small cell lung cancer, BMC Cancer 13 (2013), 464.
2. Li FF, Yang Y, Wang XL, Hong YY, Wang NF, Chen ZD, Promoter methylation of DAPK gene may contribute to the pathogenesis of nonsmall cell lung cancer: a meta-analysis, Tumour Biol 35 (2014), 6011-6020.
3. Atmaca A, Al-Batran SE, Werner D, Pauligk C, Guner T, Koepke A, Bernhard H, Wenzel T, Banat AG, Brueck P, Caca K, Prasnikar N, Kullmann F, Gunther Derigs H, Koenigsmann M, Dingeldein G, Neuhaus T, Jager E, A randomised multicentre phase II study with cisplatin/docetaxel vs oxaliplatin/docetaxel as first-line therapy in patients with advanced or metastatic non-small cell lung cancer, Br J Cancer 108 (2013), 265-270.
4. Lee SH, Suh IB, Lee EJ, Hur GY, Lee SY, Lee SY, Shin C, Shim JJ, In KH, Kang KH, Yoo SH, Kim JH, Relationships of coagulation factor XIII activity with cell-type and stage of non-small cell lung cancer, Yonsei Med J 54 (2013), 1394-1399.
5. de Mello RA, Ferreira M, Costa S, Costa BM, Pires FS, Neves I, Almeida MI, Cunha J, Oliveira P, Hespanhol V, Reis RM, Association between EGF +61 genetic polymorphisms and non-small cell lung cancer increased risk in a Portuguese population: A case-control study, Tumour Biol 33 (2012), 1341-1348.
6. Langer CJ, Mok T, Postmus PE, Targeted agents in the third-/fourth-line treatment of patients with advanced (stage III/IV) non-small cell lung cancer (NSCLC), Cancer Treat Rev 39 (2013), 252-260.
7. Wang H, Zhao Y, Ma J, Zhang G, Mu Y, Qi G, Fang Z, Wang L, Fan Q, Ma Z, The genetic variant rs401681C/T is associated with the risk of non-small cell lung cancer in a Chinese mainland population, Genet Mol Res 12 (2013), 67-73.
8. Zhu N, Gong Y, He J, Xia J, Chen X, Influence of methylenetetrahydrofolate reductase C677T polymorphism on the risk of lung cancer and the clinical response to platinum-based chemotherapy for advanced non-small cell lung cancer: An updated meta-analysis, Yonsei Med J 54 (2013), 1384-1393.
9. Michie AM, McCaig AM, Nakagawa R, Vukovic M, Death-associated protein kinase (DAPK) and signal transduction: Regulation in cancer, FEBS J 277 (2010), 74-80.
10. Kawaguchi K, Oda Y, Saito T, Yamamoto H, Takahira T, Tamiya S, Iwamoto Y, Tsuneyoshi M, Death-associated protein kinase (DAP kinase) alteration in soft tissue leiomyosarcoma: Promoter methylation or homozygous deletion is associated with a loss of DAP kinase expression, Hum Pathol 35 (2004), 1266-1271.
11. Kim CE, Tchou-Wong KM, Rom WN, Sputum-based molecular biomarkers for the early detection of lung cancer: limitations and promise, Cancers (Basel) 3 (2011), 2975-2989.
12. Nikoletopoulou V, Markaki M, Palikaras K, Tavernarakis N, Crosstalk between apoptosis, necrosis and autophagy, Biochim Biophys Acta 1833 (2013), 3448-3459.
13. Patel AK, Yadav RP, Majava V, Kursula I, Kursula P, Structure of the dimeric autoinhibited conformation of DAPK2, a proapoptotic protein kinase, J Mol Biol 409 (2011), 369-383.
14. Mor I, Carlessi R, Ast T, Feinstein E, Kimchi A, Deathassociated protein kinase increases glycolytic rate through binding and activation of pyruvate kinase, Oncogene 31 (2012), 683-693.
15. Nakav S, Cohen S, Feigelson SW, Bialik S, Shoseyov D, Kimchi A, Alon R, Tumor suppressor death-associated protein kinase attenuates inflammatory responses in the lung, Am J Respir Cell Mol Biol 46 (2012), 313-322.
16. Kuester D, Guenther T, Biesold S, Hartmann A, Bataille F, Ruemmele P, Peters B, Meyer F, Schubert D, Bohr UR, Malfertheiner P, Lippert H, Silver AR, Roessner A, Schneider-Stock R, Aberrant methylation of DAPK in longstanding ulcerative colitis and ulcerative colitis-associated carcinoma, Pathol Res Pract 206 (2010), 616-624.
17. Ahmad ST, Arjumand W, Seth A, Saini AK, Sultana S, Methylation of the APAF-1 and DAPK-1 promoter region correlates with progression of renal cell carcinoma in North Indian population, Tumour Biol 33 (2012), 395-402.
18. Hu SL, Kong XY, Cheng ZD, Sun YB, Shen G, Xu WP, Wu L, Xu XC, Jiang XD, Huang DB, Promoter methylation of p16, Runx3, DAPK and CHFR genes is frequent in gastric carcinoma, Tumori 96 (2010), 726-733.
19. Zhang Y, Wang R, Song H, Huang G, Yi J, Zheng Y, Wang J, Chen L, Methylation of multiple genes as a candidate biomarker in non-small cell lung cancer, Cancer Lett 303 (2011), 21-28.
20. Buckingham L, Penfield Faber L, Kim A, Liptay M, Barger C, Basu S, Fidler M, Walters K, Bonomi P, Coon J, PTEN, RASSF1 and DAPK site-specific hypermethylation and outcome in surgically treated stage I and II nonsmall cell lung cancer patients, Int J Cancer 126 (2010), 1630-1639.
21. Kontic M SJ, Jovanovic D, Quantitative methylation profiles of multiple genes in patients with non-small cell lung cancer and its association with clinicopathological correlations, European Respiratory Journal, 38 (2011), 1952.
22. Drilon A, Sugita H, Sima CS, Zauderer M, Rudin CM, Kris MG, Rusch VW, Azzoli CG, A prospective study of tumor suppressor gene methylation as a prognostic biomarker in surgically resected stage I to IIIA non-small-cell lung cancers, J Thorac Oncol 9 (2014), 1272-1277.
23. Chen H, Manning AK, Dupuis J, A method of moments es timator for random effect multivariate meta-analysis, Biometrics 68 (2012), 1278-1284.
24. Jackson D, White IR, Riley RD, Quantifying the impact of between-study heterogeneity in multivariate meta-analyses, Stat Med 31 (2012), 3805-3820.
25. Peters JL, Sutton AJ, Jones DR, Abrams KR, Rushton L, Comparison of two methods to detect publication bias in meta-analysis, JAMA 295 (2006), 676-680.
26. Zintzaras E, Ioannidis JP, Heterogeneity testing in metaanalysis of genome searches, Genet Epidemiol 28 (2005), 123-137.
27. Peters JL, Sutton AJ, Jones DR, Abrams KR, Rushton L, Contour-enhanced meta-analysis funnel plots help distinguish publication bias from other causes of asymmetry, J Clin Epidemiol 61 (2008), 991-996.
28. Egger M, Davey Smith G, Schneider M, Minder C, Bias in meta-analysis detected by a simple, graphical test, BMJ 315 (1997), 629-634.
29. Tang X, Khuri FR, Lee JJ, Kemp BL, Liu D, Hong WK, Mao L, Hypermethylation of the death-associated protein (DAP) kinase promoter and aggressiveness in stage I non-small-cell lung cancer, J Natl Cancer Inst 92 (2000), 1511-1516.
30. Zochbauer-Muller S, Fong KM, Virmani AK, Geradts J, Gazdar AF, Minna JD, Aberrant promoter methylation of multiple genes in non-small cell lung cancers, Cancer Res 61 (2001), 249-255.
31. Wu J, Liang B, He JY, Zhang HT, Wang ZG, Study on detection of aberrant promoter hypermethylation of p16 and DAP kinase in serum DNA from patients with non-small cell lung cancer, Chinese Journal of Lung Cancer 5 (2002), 188-190.
32. Lin Q, Chen LB, Tang YM, Wang J, Analysis of promoter hypermethylation of death-asscciated protein kinase gene in blood from non-small cell lung cancer patients, J Med Postgraduates 18 (2005), 702-705.
33. Lin Q, Chen LB, Tang YM, Wang J, Study on detection of methylation of DAPK and p16 in serum from patients with nonsmall cell lung cancers, Chinese Journal of Gerontology 26 (2006), 1304-1306.
34. Yanagawa N, Tamura G, Oizumi H, Kanauchi N, Endoh M, Sadahiro M, Motoyama T, Promoter hypermethylation of RASSF1A and RUNX3 genes as an independent prognostic prediction marker in surgically resected non-small cell lung cancers, Lung Cancer 58 (2007), 131-138.
35. Wang Y, Zhang D, Zheng W, Luo J, Bai Y, Lu Z, Multiple gene methylation of nonsmall cell lung cancers evaluated with 3-dimensional microarray, Cancer 112 (2008), 1325-1336.
36. Niklinska W, Naumnik W, Sulewska A, Kozlowski M, Pankiewicz W, Milewski R, Prognostic significance of DAPK and RASSF1A promoter hypermethylation in non-small cell lung cancer (NSCLC), Folia Histochem Cytobiol 47 (2009), 275-280.
37. Lu DG, Ji XQ, Study on detection and significance of methylation of DAPK and p16 in serum from patients with nonsmall cell lung cancers, Shandong Medical Journal 50 (2010), 69-70.
38. Peng ZM, Shan CT, Wang HF, Value of promoter methylation of RASSF1A, p16, and DAPK genes in induced sputum in diagnosing lung cancers, Journal of Central South University (Medical Science) 35 (2010), 247-253.
39. Zhang CY, Jin YT, X.u HY, Zhang H, Zhang WM, S.un XY, Tan C, Chen CM, Relationship between promoter methylation of p16, DAPK and RARβ genes and the clinical data of nonsmall cell lung cancer, Chinese Journal of Medical Genetics 28 (2011), 23-28.
40. Chen P, Wei YC, Shen Y, Relationship between Non-Small Cell Lung Cancer and Plasma Dapk Gene Methylation, Medical Journal of Qilu 27 (2012), 380-382.
41. Zhang Y, Xue SL, Song C, Jin YT, Yu ZC, Analysis of Methylation Status of DAPK Genes in Non-small Cell Lung Cancer Tissues Journal of Modern Laboratory Medicine 27 (2012), 17-18, 22.
42. Song C, Zhang Y, Jin YT, Yu ZC, Xue SL, Detection and clinical significance of DAPK gene methylation in plasma of nonsmall cell lung cancer patients, Cancer Research on Prevention and Treatment 40 (2013), 772-775.
43. Jia Y, Zang A, Shang Y, Yang H, Song Z, Wang Z, Ren L, Wei Y, Hu L, Shi H, Li H, MicroRNA-146a rs2910164 polymorphism is associated with susceptibility to non-small cell lung cancer in the Chinese population, Med Oncol 31 (2014), 194.
44. Merrow CE, Wang IZ, Podgorsak MB, A dosimetric evaluation of VMAT for the treatment of non-small cell lung cancer, J Appl Clin Med Phys 14 (2013), 4110.
45. Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA, Nonsmall cell lung cancer: Epidemiology, risk factors, treatment, and survivorship, Mayo Clin Proc 83 (2008), 584-594.
46. Huang Y, Chen L, Guo L, Hupp TR, Lin Y, Evaluating DAPK as a therapeutic target, Apoptosis 19 (2014), 371-386.
47. Schneider-Stock R, Death-associated kinase (DAPK): A cancer "gene chameleon", Apoptosis 19 (2014), 285.
48. Xiaofang L, Kun T, Shaoping Y, Zaiqiu W, Hailong S, Correlation between promoter methylation of p14(ARF), TMS1/ASC, and DAPK, and p53 mutation with prognosis in cholangiocarcinoma, World J Surg Oncol 10 (2012), 5.
49. Wang J, Wang B, Chen X, Bi J, The prognostic value of RASSF1A promoter hypermethylation in non-small cell lung carcinoma: A systematic review and meta-analysis, Carcinogenesis 32 (2011), 411-416.
50. de Fraipont F, Levallet G, Creveuil C, Bergot E, Beau-Faller M, Mounawar M, Richard N, Antoine M, Rouquette I, Favrot MC, Debieuvre D, Braun D, Westeel V, Quoix E, Brambilla E, Hainaut P, Moro-Sibilot D, Morin F, Milleron B, Zalcman G, Intergroupe Francophone de Cancerologie T, An apoptosis methylation prognostic signature for early lung cancer in the IFCT-0002 trial, Clin Cancer Res 18 (2012), 2976-2986.
51. Sulewska A, Niklinska W, Kozlowski M, Minarowski L, Naumnik W, Niklinski J, Dabrowska K, Chyczewski L, Detection of DNA methylation in eucaryotic cells, Folia Histochem Cytobiol 45 (2007), 315-324.